Case series:Continuous administration of apatinib 500mg/ days

The prospective, open-lable, single-arm, single-center clinical study of Apatinib mesylate combined with capecitabine in non-first-line treating patients with recurrent/metastatic triple-negative breast cancer

The prospective, open-lable, single-arm, single-center clinical study of Apatinib mesylate non-first-line used in treating patients with recurrent/metastatic soft tissue sarcoma.